Recent Quotes (30 days)

You have no recent quotes
chg | %

AnGes Inc  

(Public, TYO:4563)   Watch this stock  
Find more results for 4563
582.00
-15.00 (-2.51%)
Nov 20 - Close
TYO data delayed by 20 mins - Disclaimer
Currency in JPY
Range 580.00 - 593.00
52 week 225.00 - 884.00
Open 590.00
Vol. 907,500.00
Mkt cap 45.78B
P/E     -
Div/yield     -
EPS -58.38
Shares 78.67M
Beta     -
Inst. own     -
Feb 1, 2018
Full Year 2017 AnGes Inc Earnings Release (Estimated) Add to calendar
Oct 30, 2017
Q3 2017 AnGes Inc Earnings Release
  

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -1230.50% -928.85%
Operating margin -1208.51% -918.05%
EBITD margin - -913.15%
Return on average assets -92.17% -102.82%
Return on average equity -103.70% -118.08%
Employees 55 -
CDP Score - -

Address

7-7-15 Saito-asagi Saito Bio-Incubator 4 Fl.
IBARAKI-SHI, OSK 567-0085
Japan
+81-3-57302641 (Phone)

Website links

Description

AnGes, Inc., formerly AnGes MG, Inc., is a Japan-based company mainly engaged in the development of genetic medicines. The Company is involved in the development of hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, among others. As of December 31, 2012, the Company had four consolidated subsidiaries. On January 31, 2013, the Company sold a 95.3% stake of a Osaka-based subsidiary to ISHIHARA SANGYO KAISHA LTD.

Officers and directors

Ei Yamada President, Executive President, CEO of Subsidiary, Representative Director
Age: 62
Shunsuke Sami Vice President, Executive Officer, CEO of Subsidiary, Director
Age: 59
Seiji Hirasaki Executive Officer, Chief Director of Business Strategy, Director
Takahiro Nakasawa Executive Officer, Chief Director of Research and Development
Makoto Seki Executive Officer, Chief Director of Business Planning
Sadayoshi Yamanami Executive Officer, Chief Director of Credibility Assurance
Ichiro Kitazato Independent Director
Age: 80
Junichi Komamura Independent Director
Age: 63